Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 Oct;17(4):783-93, table of contents.
doi: 10.1128/CMR.17.4.783-793.2004.

Treatment of infections caused by metronidazole-resistant Trichomonas vaginalis

Sarah L Cudmore  1 , Kiera L Delgaty, Shannon F Hayward-McClelland, Dino P Petrin, Gary E Garber
Affiliations
Review

Treatment of infections caused by metronidazole-resistant Trichomonas vaginalis

Sarah L Cudmore et al. Clin Microbiol Rev. 2004 Oct.

Abstract

Infections with the sexually transmitted protozoan Trichomonas vaginalis are usually treated with metronidazole, a 5-nitroimidazole drug derived from the antibiotic azomycin. Metronidazole treatment is generally efficient in eliminating T. vaginalis infection and has a low risk of serious side effects. However, studies have shown that at least 5% of clinical cases of trichomoniasis are caused by parasites resistant to the drug. The lack of approved alternative therapies for T. vaginalis treatment means that higher and sometimes toxic doses of metronidazole are the only option for patients with resistant disease. Clearly, studies of the treatment and prevention of refractory trichomoniasis are essential. This review describes the mechanisms of metronidazole resistance in T. vaginalis and provides a summary of trichomonicidal and vaccine candidate drugs.

PubMed Disclaimer

References

    1. Abraham, M. C., M. Desjardins, L. G. Filion, and G. E. Garber. 1996. Inducible immunity to Trichomonas vaginalis in a mouse model of vaginal infection. Infect. Immun. 64:3571-3575. - PMC - PubMed
    1. Aburel, E., G. Zervos, V. Titea, and S. Pana. 1963. Immunological and therapeutic investigations in vaginal trichomoniasis. Rom. Med. Rev. 7:13-19. - PubMed
    1. Adugu, I. S., D. Nolder, D. S. Warhurst, and J. F. Rossignol. 2002. In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis. Entamoeba histolytica, and Trichomonas vaginalis. J. Antimicrob. Chemother. 49:103-111. - PubMed
    1. Ackers, J. P. 1990. Immunologic aspects of human trichomoniasis, p. 36-52. In B. M. Honigberg (ed.), Trichomonads parasitic in humans. Springer-Verlag, New York, N.Y.
    1. Addis, M. A., P. Rappelli, A. M. P. de Andrade, F. M. Rita, M. M. Colombo, P. Cappuccinelli, and P. L. Fiori. 1999. Identification of Trichomonas vaginalis α-actinin as the most common immunogen recognized by the sera of women exposed to the parasite. J. Infect. Dis. 180:1727-1730. - PubMed

MeSH terms